Literature DB >> 28187494

The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients.

Joaquín Cubiella1,2, Jayne Digby3, Lorena Rodríguez-Alonso4,5, Pablo Vega1, María Salve1, Marta Díaz-Ondina6, Judith A Strachan7, Craig Mowat8, Paula J McDonald9, Francis A Carey10, Ian M Godber11, Hakim Ben Younes12, Francisco Rodriguez-Moranta4,5, Enrique Quintero13, Victoria Álvarez-Sánchez14, Fernando Fernández-Bañares15, Jaume Boadas16, Rafel Campo17, Luis Bujanda18, Ana Garayoa19, Ángel Ferrandez20, Virginia Piñol21, Daniel Rodríguez-Alcalde22, Jordi Guardiola4,5, Robert J C Steele3, Callum G Fraser3.   

Abstract

Prediction models for colorectal cancer (CRC) detection in symptomatic patients, based on easily obtainable variables such as fecal haemoglobin concentration (f-Hb), age and sex, may simplify CRC diagnosis. We developed, and then externally validated, a multivariable prediction model, the FAST Score, with data from five diagnostic test accuracy studies that evaluated quantitative fecal immunochemical tests in symptomatic patients referred for colonoscopy. The diagnostic accuracy of the Score in derivation and validation cohorts was compared statistically with the area under the curve (AUC) and the Chi-square test. 1,572 and 3,976 patients were examined in these cohorts, respectively. For CRC, the odds ratio (OR) of the variables included in the Score were: age (years): 1.03 (95% confidence intervals (CI): 1.02-1.05), male sex: 1.6 (95% CI: 1.1-2.3) and f-Hb (0-<20 µg Hb/g feces): 2.0 (95% CI: 0.7-5.5), (20-<200 µg Hb/g): 16.8 (95% CI: 6.6-42.0), ≥200 µg Hb/g: 65.7 (95% CI: 26.3-164.1). The AUC for CRC detection was 0.88 (95% CI: 0.85-0.90) in the derivation and 0.91 (95% CI: 0.90-093; p = 0.005) in the validation cohort. At the two Score thresholds with 90% (4.50) and 99% (2.12) sensitivity for CRC, the Score had equivalent sensitivity, although the specificity was higher in the validation cohort (p < 0.001). Accordingly, the validation cohort was divided into three groups: high (21.4% of the cohort, positive predictive value-PPV: 21.7%), intermediate (59.8%, PPV: 0.9%) and low (18.8%, PPV: 0.0%) risk for CRC. The FAST Score is an easy to calculate prediction tool, highly accurate for CRC detection in symptomatic patients.
© 2017 UICC.

Entities:  

Keywords:  advanced colorectal neoplasia; colonoscopy; colorectal cancer; diagnostic accuracy; fecal immunochemical test; inflammatory bowel disease; risk stratification

Mesh:

Substances:

Year:  2017        PMID: 28187494     DOI: 10.1002/ijc.30639

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Value of Serum NEUROG1 Methylation for the Detection of Advanced Adenomas and Colorectal Cancer.

Authors:  Olalla Otero-Estévez; María Gallardo-Gomez; María Páez de la Cadena; Francisco Javier Rodríguez-Berrocal; Joaquín Cubiella; Vicent Hernandez Ramirez; Laura García-Nimo; Loretta De Chiara
Journal:  Diagnostics (Basel)       Date:  2020-06-28

2.  Impact of the faecal immunochemical test on colorectal cancer survival.

Authors:  María Angeles Gutierrez-Stampa; Vanessa Aguilar; Cristina Sarasqueta; Joaquín Cubiella; Isabel Portillo; Luis Bujanda
Journal:  BMC Cancer       Date:  2020-07-01       Impact factor: 4.430

3.  Thrombocytosis helps to stratify risk of colorectal cancer in patients referred on a 2-week-wait pathway.

Authors:  J A Bailey; N Hanbali; K Premji; J Bunce; S Mashlab; J A Simpson; D J Humes; A Banerjea
Journal:  Int J Colorectal Dis       Date:  2020-05-01       Impact factor: 2.571

4.  Comparative evaluation of novel screening strategies for colorectal cancer screening in China (TARGET-C): a study protocol for a multicentre randomised controlled trial.

Authors:  Hongda Chen; Ni Li; Jufang Shi; Jiansong Ren; Chengcheng Liu; Yueming Zhang; Zheng Jiang; Zhihui Zhang; Min Dai
Journal:  BMJ Open       Date:  2019-04-20       Impact factor: 2.692

5.  Anaemia as a risk stratification tool for symptomatic patients referred via the two-week wait pathway for colorectal cancer.

Authors:  S Mashlab; P Large; W Laing; O Ng; M D'Auria; D Thurston; S Thomson; A G Acheson; D J Humes; A Banerjea
Journal:  Ann R Coll Surg Engl       Date:  2018-03-15       Impact factor: 1.891

6.  The Fast Track FIT study: diagnostic accuracy of faecal immunochemical test for haemoglobin in patients with suspected colorectal cancer.

Authors:  James L Turvill; Daniel Turnock; Dan Cottingham; Monica Haritakis; Laura Jeffery; Annabelle Girdwood; Tom Hearfield; Alex Mitchell; Ada Keding
Journal:  Br J Gen Pract       Date:  2021-07-29       Impact factor: 6.302

Review 7.  Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance.

Authors:  Marie Westwood; Shona Lang; Nigel Armstrong; Sietze van Turenhout; Joaquín Cubiella; Lisa Stirk; Isaac Corro Ramos; Marianne Luyendijk; Remziye Zaim; Jos Kleijnen; Callum G Fraser
Journal:  BMC Med       Date:  2017-10-24       Impact factor: 8.775

8.  Not so FAST. Commentary on the article "Appraisal of the faecal haemoglobin, age and sex test (FAST) score in assessment of patients with lower bowel symptoms: an observational study".

Authors:  Joaquín Cubiella
Journal:  BMC Gastroenterol       Date:  2020-07-20       Impact factor: 3.067

9.  Targeted UPLC-MS Metabolic Analysis of Human Faeces Reveals Novel Low-Invasive Candidate Markers for Colorectal Cancer.

Authors:  Joaquin Cubiella; Marc Clos-Garcia; Cristina Alonso; Ibon Martinez-Arranz; Miriam Perez-Cormenzana; Ziortza Barrenetxea; Jesus Berganza; Isabel Rodríguez-Llopis; Mauro D'Amato; Luis Bujanda; Marta Diaz-Ondina; Juan M Falcón-Pérez
Journal:  Cancers (Basel)       Date:  2018-09-01       Impact factor: 6.639

10.  Symptom or faecal immunochemical test based referral criteria for colorectal cancer detection in symptomatic patients: a diagnostic tests study.

Authors:  Jesús-Miguel Herrero; Pablo Vega; María Salve; Luis Bujanda; Joaquín Cubiella
Journal:  BMC Gastroenterol       Date:  2018-10-25       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.